{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:28:44Z","timestamp":1786663724717,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA278889"],"award-info":[{"award-number":["R01CA278889"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA275990"],"award-info":[{"award-number":["R01CA275990"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA247992"],"award-info":[{"award-number":["R01CA247992"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269646"],"award-info":[{"award-number":["R01CA269646"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274220"],"award-info":[{"award-number":["U54CA274220"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC230358"],"award-info":[{"award-number":["PC230358"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["FP00016492"],"award-info":[{"award-number":["FP00016492"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR190021"],"award-info":[{"award-number":["RR190021"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210028"],"award-info":[{"award-number":["RP210028"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP230072"],"award-info":[{"award-number":["RP230072"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R25CA240137-01A1"],"award-info":[{"award-number":["1R25CA240137-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Genetic heterogeneity contributes to the variable therapeutic responses in cancers. Frequent\n                    <jats:italic>SPOP<\/jats:italic>\n                    mutations and recurrent\n                    <jats:italic>CHD1<\/jats:italic>\n                    deletions define distinct molecular subtypes of prostate cancer (PCa) with differential responses to anti-androgen therapy. Ferroptosis, an iron-dependent cell death mechanism driven by lipid peroxidation, has emerged as a promising anticancer strategy. Here, we identify\n                    <jats:italic>SPOP<\/jats:italic>\n                    mutations and\n                    <jats:italic>CHD1<\/jats:italic>\n                    deletion as key genetic determinants of ferroptosis susceptibility in PCa. Using genetically engineered human and murine models, we show that\n                    <jats:italic>SPOP<\/jats:italic>\n                    mutations enhance, whereas\n                    <jats:italic>CHD1<\/jats:italic>\n                    deletion impairs, the efficacy of ferroptosis inducers targeting GPX4. Mechanistically, SPOP and CHD1 exert opposing effects on ferroptosis by antagonistically regulating the MYC\u2013ACSL4 axis. Furthermore, we demonstrate that targeting cholesterol metabolism with cholesterol-lowering agents restores ACSL4 expression and re-sensitizes\n                    <jats:italic>SPOP\/CHD1<\/jats:italic>\n                    co-deficient tumors to ferroptosis-inducing therapy. Our findings establish SPOP\/CHD1 as upstream genetic regulators of ferroptosis and provide biomarker-driven combinatorial strategies to enhance ferroptosis-based therapy in men with advanced PCa.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75010-y","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:39:25Z","timestamp":1782859165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis"],"prefix":"10.1038","volume":"17","author":[{"given":"Feiyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-8576","authenticated-orcid":false,"given":"Qidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-6011","authenticated-orcid":false,"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naayaa","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-8122","authenticated-orcid":false,"given":"Iqbal","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco R.","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya M.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-471X","authenticated-orcid":false,"given":"Daniel E.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-6040","authenticated-orcid":false,"given":"Boyi","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-7127","authenticated-orcid":false,"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"75010_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"75010_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"75010_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304 e296 (2018).","journal-title":"Cell"},{"key":"75010_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"75010_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"The Cancer Genome Atlas Research Network","year":"2015","unstructured":"The Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"75010_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature09744","volume":"470","author":"MF Berger","year":"2011","unstructured":"Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214\u2013220 (2011).","journal-title":"Nature"},{"key":"75010_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685\u2013689 (2012).","journal-title":"Nat. Genet."},{"key":"75010_CR8","doi-asserted-by":"publisher","first-page":"e09207","DOI":"10.7554\/eLife.09207","volume":"4","author":"G Boysen","year":"2015","unstructured":"Boysen, G. et al. SPOP mutation leads to genomic instability in prostate cancer. Elife 4, e09207 (2015).","journal-title":"Elife"},{"key":"75010_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 162, 454 (2015).","journal-title":"Cell"},{"key":"75010_CR10","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1038\/onc.2017.80","volume":"36","author":"C Geng","year":"2017","unstructured":"Geng, C. et al. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene 36, 4767\u20134777 (2017).","journal-title":"Oncogene"},{"key":"75010_CR11","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","volume":"74","author":"C Geng","year":"2014","unstructured":"Geng, C. et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 74, 5631\u20135643 (2014).","journal-title":"Cancer Res."},{"key":"75010_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","volume":"6","author":"J An","year":"2014","unstructured":"An, J., Wang, C., Deng, Y., Yu, L. & Huang, H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 6, 657\u2013669 (2014).","journal-title":"Cell Rep."},{"key":"75010_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.molcel.2015.07.026","volume":"59","author":"W Gan","year":"2015","unstructured":"Gan, W. et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917\u2013930 (2015).","journal-title":"Mol. Cell"},{"key":"75010_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2015.07.025","volume":"59","author":"J An","year":"2015","unstructured":"An, J. et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904\u2013916 (2015).","journal-title":"Mol. Cell"},{"key":"75010_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccell.2016.04.012","volume":"29","author":"AC Groner","year":"2016","unstructured":"Groner, A. C. et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 29, 846\u2013858 (2016).","journal-title":"Cancer Cell"},{"key":"75010_CR16","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1038\/onc.2011.151","volume":"30","author":"C Li","year":"2011","unstructured":"Li, C. et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3\/AIB1. Oncogene 30, 4350\u20134364 (2011).","journal-title":"Oncogene"},{"key":"75010_CR17","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1073\/pnas.1304502110","volume":"110","author":"C Geng","year":"2013","unstructured":"Geng, C. et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA. 110, 6997\u20137002 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75010_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.molcel.2009.09.022","volume":"36","author":"M Zhuang","year":"2009","unstructured":"Zhuang, M. et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 36, 39\u201350 (2009).","journal-title":"Mol. Cell"},{"key":"75010_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","volume":"78","author":"U Swami","year":"2020","unstructured":"Swami, U. et al. Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer. Eur. Urol. 78, 652\u2013656 (2020).","journal-title":"Eur. Urol."},{"key":"75010_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/pros.24269","volume":"82","author":"M Nakazawa","year":"2022","unstructured":"Nakazawa, M. et al. Clinical and genomic features of SPOP-mutant prostate cancer. Prostate 82, 260\u2013268 (2022).","journal-title":"Prostate"},{"key":"75010_CR21","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","volume":"26","author":"KH Stopsack","year":"2020","unstructured":"Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230\u20133238 (2020).","journal-title":"Clin. Cancer Res."},{"key":"75010_CR22","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","volume":"28","author":"U Swami","year":"2022","unstructured":"Swami, U. et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 28, 4917\u20134925 (2022).","journal-title":"Clin. Cancer Res."},{"key":"75010_CR23","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","volume":"24","author":"G Boysen","year":"2018","unstructured":"Boysen, G. et al. SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity. Clin. Cancer Res. 24, 5585\u20135593 (2018).","journal-title":"Clin. Cancer Res."},{"key":"75010_CR24","doi-asserted-by":"publisher","first-page":"e147878","DOI":"10.1172\/JCI147878","volume":"131","author":"D Liu","year":"2021","unstructured":"Liu, D. et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J. Clin. Invest. 131, e147878 (2021).","journal-title":"J. Clin. Invest."},{"key":"75010_CR25","doi-asserted-by":"publisher","first-page":"16279","DOI":"10.1074\/jbc.M600682200","volume":"281","author":"C Stockdale","year":"2006","unstructured":"Stockdale, C., Flaus, A., Ferreira, H. & Owen-Hughes, T. Analysis of nucleosome repositioning by yeast ISWI and Chd1 chromatin remodeling complexes. J. Biol. Chem. 281, 16279\u201316288 (2006).","journal-title":"J. Biol. Chem."},{"key":"75010_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nsmb884","volume":"12","author":"A Lusser","year":"2005","unstructured":"Lusser, A., Urwin, D. L. & Kadonaga, J. T. Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. Nat. Struct. Mol. Biol. 12, 160\u2013166 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"75010_CR27","doi-asserted-by":"publisher","first-page":"1123362","DOI":"10.3389\/fonc.2023.1123362","volume":"13","author":"H Li","year":"2023","unstructured":"Li, H., Gigi, L. & Zhao, D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Front. Oncol. 13, 1123362 (2023).","journal-title":"Front. Oncol."},{"key":"75010_CR28","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-12-1342","volume":"73","author":"L Burkhardt","year":"2013","unstructured":"Burkhardt, L. et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73, 2795\u20132805 (2013).","journal-title":"Cancer Res."},{"key":"75010_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello, M. A. et al. CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell 35, 603\u2013617 e608 (2019).","journal-title":"Cancer Cell"},{"key":"75010_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","volume":"37","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell 37, 584\u2013598 e511 (2020).","journal-title":"Cancer Cell"},{"key":"75010_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nsmb.3153","volume":"23","author":"E Metzger","year":"2016","unstructured":"Metzger, E. et al. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat. Struct. Mol. Biol. 23, 132\u2013139 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"75010_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-14-1596","volume":"75","author":"LU Rodrigues","year":"2015","unstructured":"Rodrigues, L. U. et al. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 75, 1021\u20131034 (2015).","journal-title":"Cancer Res."},{"key":"75010_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/1541-7786.MCR-20-0913","volume":"19","author":"LK Jillson","year":"2021","unstructured":"Jillson, L. K. et al. MAP3K7 loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate cancer with joint loss of CHD1. Mol. Cancer Res. 19, 1123\u20131136 (2021).","journal-title":"Mol. Cancer Res."},{"key":"75010_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature21357","volume":"542","author":"D Zhao","year":"2017","unstructured":"Zhao, D. et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542, 484\u2013488 (2017).","journal-title":"Nature"},{"key":"75010_CR35","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","volume":"10","author":"D Zhao","year":"2020","unstructured":"Zhao, D. et al. Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discov. 10, 1374\u20131387 (2020).","journal-title":"Cancer Discov."},{"key":"75010_CR36","doi-asserted-by":"crossref","unstructured":"Chen, F. et al. CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors. Nat. Cancer 6, 854\u2013873 (2025).","DOI":"10.1038\/s43018-025-00952-z"},{"key":"75010_CR37","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"75010_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75010_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91\u201398 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"75010_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381\u2013396 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"75010_CR41","doi-asserted-by":"publisher","first-page":"e166647","DOI":"10.1172\/JCI166647","volume":"133","author":"ME Wang","year":"2023","unstructured":"Wang, M. E. et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis. J. Clin. Invest. 133, e166647 (2023).","journal-title":"J. Clin. Invest."},{"key":"75010_CR42","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1158\/2159-8290.CD-23-1220","volume":"14","author":"G Lei","year":"2024","unstructured":"Lei, G. et al. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer Discov. 14, 1476\u20131495 (2024).","journal-title":"Cancer Discov."},{"key":"75010_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-024-00869-9","volume":"21","author":"PHA Cao","year":"2024","unstructured":"Cao, P. H. A. et al. Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers. Nat. Rev. Urol. 21, 615\u2013637 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"75010_CR44","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","volume":"186","author":"D Liang","year":"2023","unstructured":"Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748\u20132764 e2722 (2023).","journal-title":"Cell"},{"key":"75010_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","volume":"31","author":"M Blattner","year":"2017","unstructured":"Blattner, M. et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling. Cancer Cell 31, 436\u2013451 (2017).","journal-title":"Cancer Cell"},{"key":"75010_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07254-9","volume":"15","author":"N Sun","year":"2024","unstructured":"Sun, N. et al. Oncogenic RTKs sensitize cancer cells to ferroptosis via c-Myc mediated upregulation of ACSL4. Cell Death Dis. 15, 861 (2024).","journal-title":"Cell Death Dis."},{"key":"75010_CR47","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1158\/1078-0432.CCR-23-2438","volume":"30","author":"N Anselmino","year":"2024","unstructured":"Anselmino, N. et al. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin. Cancer Res. 30, 2272\u20132285 (2024).","journal-title":"Clin. Cancer Res."},{"key":"75010_CR48","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","volume":"16","author":"JK Eaton","year":"2020","unstructured":"Eaton, J. K. et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat. Chem. Biol. 16, 497\u2013506 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"75010_CR49","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"Luirink, I. K. et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N. Engl. J. Med. 381, 1547\u20131556 (2019).","journal-title":"N. Engl. J. Med."},{"key":"75010_CR50","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1074\/jbc.M407941200","volume":"280","author":"S Cao","year":"2005","unstructured":"Cao, S. et al. KLF11-mediated repression antagonizes Sp1\/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling. J. Biol. Chem. 280, 1901\u20131910 (2005).","journal-title":"J. Biol. Chem."},{"key":"75010_CR51","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1038\/s41418-019-0299-4","volume":"26","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia\/reperfusion. Cell Death Differ. 26, 2284\u20132299 (2019).","journal-title":"Cell Death Differ."},{"key":"75010_CR52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"75010_CR53","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180\u20131191 (2014).","journal-title":"Nat. Cell Biol."},{"key":"75010_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"75010_CR55","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-23-2796","volume":"85","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. JMJD6 rewires ATF4-dependent glutathione metabolism to confer ferroptosis resistance in SPOP-mutated prostate cancer. Cancer Res. 85, 1496\u20131513 (2025).","journal-title":"Cancer Res."},{"key":"75010_CR56","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.chembiol.2022.06.004","volume":"29","author":"L Magtanong","year":"2022","unstructured":"Magtanong, L. et al. Context-dependent regulation of ferroptosis sensitivity. Cell Chem. Biol. 29, 1409\u20131418 e1406 (2022).","journal-title":"Cell Chem. Biol."},{"key":"75010_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u2013358 (2016).","journal-title":"Nat. Protoc."},{"key":"75010_CR58","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1158\/0008-5472.CAN-22-0631","volume":"82","author":"H Li","year":"2022","unstructured":"Li, H. et al. CHD1 promotes sensitivity to aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Res. 82, 3088\u20133101 (2022).","journal-title":"Cancer Res."},{"key":"75010_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"75010_CR60","doi-asserted-by":"publisher","first-page":"D1331","DOI":"10.1093\/nar\/gkaf1250","volume":"54","author":"J Casper","year":"2026","unstructured":"Casper, J. et al. The UCSC Genome Browser database: 2026 update. Nucleic Acids Res. 54, D1331\u2013D1335 (2026).","journal-title":"Nucleic Acids Res."},{"key":"75010_CR61","doi-asserted-by":"publisher","first-page":"D966","DOI":"10.1093\/nar\/gkae1078","volume":"53","author":"JM Mudge","year":"2025","unstructured":"Mudge, J. M. et al. GENCODE 2025: reference gene annotation for human and mouse. Nucleic Acids Res. 53, D966\u2013D975 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75010-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75010-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75010-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:08:55Z","timestamp":1786662535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75010-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75010"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75010-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.Frigo has a familial relationship with March Biosciences, Biocity Biopharmaceuticals, and Barricade Therapeutics. The authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8385"}}